Search research articles
Contact Us
Filters
Showing results (121-130 of 143) with videos related to
Page
of 15
Sort By:
Eclinicalmedicine
|
September 19, 2025
Impact of platinum-based chemotherapy and CTLA-4 inhibition on acquired resistance to first-line anti-PD-1/PD-L1 agents in non-small cell lung cancer: a systematic review and reconstructed individual patient data analysis
Sara Oresti, Fabio Salomone, Antonio Nuccio, et al.
Clinical Lung Cancer
|
August 10, 2022
Circulating Fatty Acid Profile as a Biomarker for Immunotherapy in Advanced Non-Small Cell Lung Cancer
Giulia Galli, Paola Antonia Corsetto, Claudia Proto, et al.
Critical Reviews in Oncology/Hematology
|
December 13, 2021
The challenge of the Molecular Tumor Board empowerment in clinical oncology practice: A Position Paper on behalf of the AIOM- SIAPEC/IAP-SIBioC-SIC-SIF-SIGU-SIRM Italian Scientific Societies
Antonio Russo, Lorena Incorvaia, Ettore Capoluongo, et al.
Lung Cancer (Amsterdam, Netherlands)
|
November 2, 2023
High bone tumor burden to identify advanced non-small cell lung cancer patients with survival benefit upon bone targeted agents and immune checkpoint inhibitors
Sara Manglaviti, Marta Bini, Giulia Apollonio, et al.
JAMA Oncology
|
September 8, 2018
Hyperprogressive Disease in Patients With Advanced Non-Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy
Roberto Ferrara, Laura Mezquita, Matthieu Texier, et al.
Clinical Lung Cancer
|
September 29, 2023
Exploring the Role of Immunotherapy-Based Treatments for Advanced Non-Small-Cell Lung Cancer With Novel Driver Alterations
Marta Brambilla, Teresa Beninato, Anna Piemontese, et al.
JCO Precision Oncology
|
January 20, 2022
Comparison of Fast-Progression, Hyperprogressive Disease, and Early Deaths in Advanced Non-Small-Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or Chemotherapy
Roberto Ferrara, Laura Mezquita, Matthieu Texier, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 11, 2022
Comparative assessment of early mortality risk upon immune checkpoint inhibitors alone or in combination with other agents across solid malignancies: a systematic review and meta-analysis
Giuseppe Viscardi, Antonino C Tralongo, Francesco Massari, et al.
Cancer Treatment Reviews
|
June 1, 2026
PD-(L)1 containing rechallenge strategies in patients with advanced NSCLC previously treated with immunotherapy: A systematic review and meta-analysis across resistance phenotypes
Daniele Marinelli, Fabrizio Citarella, Andrea Torchia, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
April 23, 2026
First-line integration of Local Ablative Therapy (LAT) with EGFR Tyrosine Kinase Inhibitors (TKIs) in advanced EGFR+ NSCLC: A Systematic Review and Meta-Analysis
Leonardo Brunetti, Giacomo Colella, Giuseppina Rita Di Fazio, et al.
Page
of 15
Search research articles
Search
Showing results (121-130 of 143) with videos related to
Sort By:
Page
of 15
Eclinicalmedicine
|
September 19, 2025
Impact of platinum-based chemotherapy and CTLA-4 inhibition on acquired resistance to first-line anti-PD-1/PD-L1 agents in non-small cell lung cancer: a systematic review and reconstructed individual patient data analysis
Sara Oresti, Fabio Salomone, Antonio Nuccio, et al.
Clinical Lung Cancer
|
August 10, 2022
Circulating Fatty Acid Profile as a Biomarker for Immunotherapy in Advanced Non-Small Cell Lung Cancer
Giulia Galli, Paola Antonia Corsetto, Claudia Proto, et al.
Critical Reviews in Oncology/Hematology
|
December 13, 2021
The challenge of the Molecular Tumor Board empowerment in clinical oncology practice: A Position Paper on behalf of the AIOM- SIAPEC/IAP-SIBioC-SIC-SIF-SIGU-SIRM Italian Scientific Societies
Antonio Russo, Lorena Incorvaia, Ettore Capoluongo, et al.
Lung Cancer (Amsterdam, Netherlands)
|
November 2, 2023
High bone tumor burden to identify advanced non-small cell lung cancer patients with survival benefit upon bone targeted agents and immune checkpoint inhibitors
Sara Manglaviti, Marta Bini, Giulia Apollonio, et al.
JAMA Oncology
|
September 8, 2018
Hyperprogressive Disease in Patients With Advanced Non-Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy
Roberto Ferrara, Laura Mezquita, Matthieu Texier, et al.
Clinical Lung Cancer
|
September 29, 2023
Exploring the Role of Immunotherapy-Based Treatments for Advanced Non-Small-Cell Lung Cancer With Novel Driver Alterations
Marta Brambilla, Teresa Beninato, Anna Piemontese, et al.
JCO Precision Oncology
|
January 20, 2022
Comparison of Fast-Progression, Hyperprogressive Disease, and Early Deaths in Advanced Non-Small-Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or Chemotherapy
Roberto Ferrara, Laura Mezquita, Matthieu Texier, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 11, 2022
Comparative assessment of early mortality risk upon immune checkpoint inhibitors alone or in combination with other agents across solid malignancies: a systematic review and meta-analysis
Giuseppe Viscardi, Antonino C Tralongo, Francesco Massari, et al.
Cancer Treatment Reviews
|
June 1, 2026
PD-(L)1 containing rechallenge strategies in patients with advanced NSCLC previously treated with immunotherapy: A systematic review and meta-analysis across resistance phenotypes
Daniele Marinelli, Fabrizio Citarella, Andrea Torchia, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
April 23, 2026
First-line integration of Local Ablative Therapy (LAT) with EGFR Tyrosine Kinase Inhibitors (TKIs) in advanced EGFR+ NSCLC: A Systematic Review and Meta-Analysis
Leonardo Brunetti, Giacomo Colella, Giuseppina Rita Di Fazio, et al.
Page
of 15